Cargando…
Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin
Adriamycin, a widely used anthracycline antibiotic in multiple chemotherapy regimens, has been challenged by the cardiotoxicity leading to fatal congestive heart failure in the worst condition. The present study demonstrated that Dihydromyricetin, a natural product extracted from ampelopsis grossede...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413651/ https://www.ncbi.nlm.nih.gov/pubmed/25226612 |
_version_ | 1782368815556853760 |
---|---|
author | Zhu, Hong Luo, Peihua Fu, Yingying Wang, Jincheng Dai, Jiabin Shao, Jinjin Yang, Xiaochun Chang, Linlin Weng, Qinjie Yang, Bo He, Qiaojun |
author_facet | Zhu, Hong Luo, Peihua Fu, Yingying Wang, Jincheng Dai, Jiabin Shao, Jinjin Yang, Xiaochun Chang, Linlin Weng, Qinjie Yang, Bo He, Qiaojun |
author_sort | Zhu, Hong |
collection | PubMed |
description | Adriamycin, a widely used anthracycline antibiotic in multiple chemotherapy regimens, has been challenged by the cardiotoxicity leading to fatal congestive heart failure in the worst condition. The present study demonstrated that Dihydromyricetin, a natural product extracted from ampelopsis grossedentat, exerted cardioprotective effect against the injury in Adriamycin-administrated ICR mice. Dihydromyricetin decreased ALT, LDH and CKMB levels in mice serum, causing a significant reduction in the toxic death triggered by Adriamycin. The protective effects were also indicated by the alleviation of abnormal electrocardiographic changes, the abrogation of proliferation arrest and apoptotic cell death in primary myocardial cells. Further study revealed that Dihydromyricetin-rescued loss of anti-apoptosis protein ARC provoked by Adriamycin was involved in the cardioprotection. Intriguingly, the anticancer activity of Adriamycin was not compromised upon the combination with Dihydromyricetin, as demonstrated by the enhanced anticancer effect achieved by Adriamycin plus Dihydromyricetin in human leukemia U937 cells and xenograft models, in a p53-dependent manner. These results collectively promised the potential value of Dihydromyricetin as a rational cardioprotective agent of Adriamycin, by protecting myocardial cells from apoptosis, while potentiating anticancer activities of Adriamycin, thus further increasing the therapeutic window of the latter one. |
format | Online Article Text |
id | pubmed-4413651 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-44136512015-05-08 Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin Zhu, Hong Luo, Peihua Fu, Yingying Wang, Jincheng Dai, Jiabin Shao, Jinjin Yang, Xiaochun Chang, Linlin Weng, Qinjie Yang, Bo He, Qiaojun Oncotarget Research Paper Adriamycin, a widely used anthracycline antibiotic in multiple chemotherapy regimens, has been challenged by the cardiotoxicity leading to fatal congestive heart failure in the worst condition. The present study demonstrated that Dihydromyricetin, a natural product extracted from ampelopsis grossedentat, exerted cardioprotective effect against the injury in Adriamycin-administrated ICR mice. Dihydromyricetin decreased ALT, LDH and CKMB levels in mice serum, causing a significant reduction in the toxic death triggered by Adriamycin. The protective effects were also indicated by the alleviation of abnormal electrocardiographic changes, the abrogation of proliferation arrest and apoptotic cell death in primary myocardial cells. Further study revealed that Dihydromyricetin-rescued loss of anti-apoptosis protein ARC provoked by Adriamycin was involved in the cardioprotection. Intriguingly, the anticancer activity of Adriamycin was not compromised upon the combination with Dihydromyricetin, as demonstrated by the enhanced anticancer effect achieved by Adriamycin plus Dihydromyricetin in human leukemia U937 cells and xenograft models, in a p53-dependent manner. These results collectively promised the potential value of Dihydromyricetin as a rational cardioprotective agent of Adriamycin, by protecting myocardial cells from apoptosis, while potentiating anticancer activities of Adriamycin, thus further increasing the therapeutic window of the latter one. Impact Journals LLC 2014-09-05 /pmc/articles/PMC4413651/ /pubmed/25226612 Text en Copyright: © 2015 Zhu et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Zhu, Hong Luo, Peihua Fu, Yingying Wang, Jincheng Dai, Jiabin Shao, Jinjin Yang, Xiaochun Chang, Linlin Weng, Qinjie Yang, Bo He, Qiaojun Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin |
title | Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin |
title_full | Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin |
title_fullStr | Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin |
title_full_unstemmed | Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin |
title_short | Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin |
title_sort | dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413651/ https://www.ncbi.nlm.nih.gov/pubmed/25226612 |
work_keys_str_mv | AT zhuhong dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin AT luopeihua dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin AT fuyingying dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin AT wangjincheng dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin AT daijiabin dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin AT shaojinjin dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin AT yangxiaochun dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin AT changlinlin dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin AT wengqinjie dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin AT yangbo dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin AT heqiaojun dihydromyricetinpreventscardiotoxicityandenhancesanticanceractivityinducedbyadriamycin |